Skip to main content
SpringerLink
Log in

Forschung in urologischen Universitätskliniken

Bestandaufnahme und Perspektiven

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Adams J, Kiss E, Arroyo AB et al. (2005) 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am J Pathol 167: 285–298

    PubMed  Google Scholar 

  2. Aigner A, Brachmann P, Beyer J et al. (2003) Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol 14: 1525–1529

    Article  PubMed  Google Scholar 

  3. Albers P, Siener R, Kliesch S et al. (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21: 1505–1512

    Article  PubMed  Google Scholar 

  4. Bastian PJ, Palapattu GS, Lin X et al. (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11: 4037–4043

    Article  PubMed  Google Scholar 

  5. Bernhardt TM, Schmidl H, Philipp C et al. (2003) Diagnostic potential of virtual cystoscopy of the bladder: MRI vs CT. Preliminary report. Eur Radiol 13: 305–312

    PubMed  Google Scholar 

  6. Blaheta RA, Bogossian H, Beecken WD, Jonas D, Hasenberg C, Makarevic J, Ogbomo H, Bechstein WO, Oppermann E et al. (2003) Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro. Transplantation 76: 1735–1741

    Article  PubMed  Google Scholar 

  7. Blaheta RA, Beecken WD, Engl T et al. (2004) Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness. Neoplasia 6: 323–331

    Article  PubMed  Google Scholar 

  8. Braun PM, Seif C, Bross S (2003) Stimulation signal modification in a porcine model for suppression of unstable detrusor contractions. Urology 61: 839–844

    Article  PubMed  Google Scholar 

  9. Buchner A, Riesenberg R, Kotter I et al. (2003) Detection and prognostic value of cytokeratin positive tumor cells in bone marrow of patients with renal cell carcinoma. J Urol 170: 1747–1751

    Article  PubMed  Google Scholar 

  10. Dieckmann KP, Albers P, Classen J et al. (2005) Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 173: 824–829

    Article  PubMed  Google Scholar 

  11. Diemer T, Allen JA, Hales KH, Hales DB (2003) Reactive oxygen disrupts mitochondria in MA-10 tumor Leydig cells and inhibits steroidogenic acute regulatory (StAR) protein and steroidogenesis. Endocrinology 144: 2882–2891

    Article  PubMed  Google Scholar 

  12. Engehausen DG, Krause FS, Fleischmann J et al. (2005) Polymorphisms of human androgen receptor (hAR) gene in prostate cancer cell lines PC-EW and PC-OR. Anticancer Res 25: 1611–1614

    PubMed  Google Scholar 

  13. Fenic I, Franke F, Failing K et al. (2004) Expression of PTEN in malignant and non-malignant human prostate tissues: comparison with p27 protein expression. J Pathol 203: 559–566

    Article  PubMed  Google Scholar 

  14. Fischer K, Loertzer H, Fornara P (2005) The use of complexed PSA for the early detection of prostate cancer. Anticancer Res 25: 1591–1596

    PubMed  Google Scholar 

  15. Fornara P, Gerbershagen HP (2004) Ultrasound in patients affected with Peyronie’s disease. World J Urol 22: 365–367

    Article  PubMed  Google Scholar 

  16. Frey UH, Eisenhardt A, Lummen G et al. (2005) The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 14: 871–877

    Article  PubMed  Google Scholar 

  17. Friedrich MG, Weisenberger DJ, Cheng JC et al. (2004) Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 10: 7457–7465

    Article  PubMed  Google Scholar 

  18. Froehner M, Koch R, Litz RJ et al. (2005) Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy. Eur Urol 47: 190–195

    Article  PubMed  Google Scholar 

  19. Ganzer R, Kohler D, Neuhaus J et al. (2004) Is the rhesus monkey (Macaca mulatta) comparable to humans? Histomorphology of the sphincteric musculature of the lower urinary tract including 3D-reconstruction. Anat Histol Embryol 33: 355–361

    Article  PubMed  Google Scholar 

  20. Haese A, Chaudhari M, Miller MC et al. (2003) Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study. Cancer 97: 969–978

    Article  PubMed  Google Scholar 

  21. Haferkamp A, Dorsam J, Resnick NM et al. (2003) Structural basis of neurogenic bladder dysfunction. III. Intrinsic detrusor innervation. J Urol 169: 555–562

    Article  PubMed  Google Scholar 

  22. Haferkamp A, Mundhenk J, Bastian PJ et al. (2004) Increased expression of connexin 43 in the overactive neurogenic detrusor. Eur Urol 46: 799–805

    Article  PubMed  Google Scholar 

  23. Hakenberg OW, Fuessel S, Richter K et al. (2004) Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 64: 1121–1126

    Article  PubMed  Google Scholar 

  24. Hegele A, Dalpke A, Heeg K et al. (2005) Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol 26: 274–280

    Article  PubMed  Google Scholar 

  25. Heidenreich A, Sommer F, Ohlmann CH et al. (2004) Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 101: 948–956

    Article  PubMed  Google Scholar 

  26. Heuser M, Ringert RH, Zoeller G, Hemmerlein B (2003) Dynamic assessment of angiogenesis in renal cell carcinoma spheroids by intravital microscopy. J Urol 169: 1267–1270

    Article  PubMed  Google Scholar 

  27. Jabs WJ, Busse M, Kruger S et al. (2005) Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 68: 2103–2110

    Article  PubMed  Google Scholar 

  28. Jocham D, Richter A, Hoffmann L et al. (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594–599

    Article  PubMed  Google Scholar 

  29. Johannsen M, Thiesen B, Jordan A et al. (2005) Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate 64: 283–292

    Article  PubMed  Google Scholar 

  30. Jones J, Otu H, Spentzos D et al. (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11: 5730–5739

    Article  PubMed  Google Scholar 

  31. Jung K, Reiche J, Boehme A et al. (2004) Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer. Clin Chem 50: 2292–2301

    Article  PubMed  Google Scholar 

  32. Junker K, Boerner D, Schulze W et al. (2003) Analysis of genetic alterations in normal bladder urothelium. Urology 62: 1134–1138

    Article  PubMed  Google Scholar 

  33. Kallwellis-Opara A, Zaho X, Zimmermann U et al. (2003) Characterization of cis-elements mediating the stimulation of glucose-6-phosphate transporter promoter activity by glucocorticoids. Gene 320: 59–66

    Article  PubMed  Google Scholar 

  34. Kammerer R, Riesenberg R, Weiler C et al. (2004) The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma. J Pathol 204: 258–267

    Article  PubMed  Google Scholar 

  35. Kausch I, Lingnau A, Endl E et al. (2003) Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer 105: 710–716

    Article  PubMed  Google Scholar 

  36. Kindich R, Florl AR, Jung V et al. (2005) Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. Clin Chem 51: 649–652

    Article  PubMed  Google Scholar 

  37. Klonisch T, Muller-Huesmann H, Riedel M et al. (2005) INSL3 in the benign hyperplastic and neoplastic human prostate gland. Int J Oncol 27: 307–315

    PubMed  Google Scholar 

  38. Konig JE, Senge T, Allhoff EP, Konig W (2004) Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58: 121–129

    Article  PubMed  Google Scholar 

  39. Konig K, Scheipers U, Pesavento A et al. (2005) Initial experiences with real-time elastography guided biopsies of the prostate. J Urol 174: 115–117

    Article  PubMed  Google Scholar 

  40. Kraemer K, Fuessel S, Schmidt U et al. (2003) Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 9: 3794–9800

    PubMed  Google Scholar 

  41. Krause FS, Feil G, Bichler KH et al. (2003) Clinical aspects for the use of DNA image cytometry in detection of bladder cancer: a valuable tool? DNA Cell Biol 22: 721–725

    Article  PubMed  Google Scholar 

  42. Kuczyk M, Turkeri L, Hammerer P, Ravery V (2003) Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol 44: 57–64

    Article  PubMed  Google Scholar 

  43. Kuefer R, Hofer MD, Gschwend JE et al. (2003) The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 9: 6447–6452

    PubMed  Google Scholar 

  44. Kuhtz-Buschbeck JP, van der Horst C et al. (2005) Cortical representation of the urge to void: a functional magnetic resonance imaging study. J Urol 174: 1477–1481

    Article  PubMed  Google Scholar 

  45. Lehmann J, Retz M, Nurnberg N et al. (2004) The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 101: 1552–1562

    Article  PubMed  Google Scholar 

  46. Lehmann J, Retz M, Wiemers C et al. (2005) Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23: 4963–4974

    Article  PubMed  Google Scholar 

  47. Lehnigk U, Zimmermann U, Woenckhaus C, Giebel J (2005) Localization of annexins I, II, IV and VII in whole prostate sections from radical prostatectomy patients. Histol Histopathol 20: 673–680

    PubMed  Google Scholar 

  48. Leissner J, Ghoneim MA, Abol-Enein H et al. (2004) Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 171: 139–144

    Article  PubMed  Google Scholar 

  49. Machtens S, Ckert S, Stief CG et al. (2003) Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro. Urology 61: 479–483

    Article  PubMed  Google Scholar 

  50. Nathanson KL, Kanetsky PA, Hawes R et al. (2005) The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet 77: 1034–1043

    Article  PubMed  Google Scholar 

  51. Oberpenning F, Hetzel S, Weining C et al. (2003) Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol 43: 478–484

    Article  PubMed  Google Scholar 

  52. Pannek J, Berges RR, Cubick G et al. (2003) Prostate size and PSA serum levels in male patients with spinal cord injury. Urology 62: 845–848

    Article  PubMed  Google Scholar 

  53. Retz M, Lehmann J, Amann E et al. (2003) Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J Urol 169: 86–89

    Article  PubMed  Google Scholar 

  54. Rubben H, Schalkhauser K, Wolff J, Luboldt HJ (2003) German Cancer Society e.V. S3 guideline for PSA determination in diagnosis of prostatic carcinoma. Onkologie 26: 88–89

    Article  PubMed  Google Scholar 

  55. Samuel U, Guggenbichler JP (2004) Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. Int J Antimicrob Agents 23(Suppl 1): 75–78

    Article  Google Scholar 

  56. Schrader AJ, Lauber J, Lechner O et al. (2003) Application of real-time reverse transcriptase-polymerase chain reaction in urological oncology. J Urol 169: 1858–1864

    Article  PubMed  Google Scholar 

  57. Schrader M, Weissbach L, Muller M et al. (2004) Detection of germ-cell-tumor-specific gene products in peripheral blood by immunomagnetic tumor cell enrichment followed by RT-PCR. Int J Mol Med 13: 685–690

    PubMed  Google Scholar 

  58. Schultheiss D, Pilatz A, Gabouev AI et al. (2004) Cytotoxicity of different intracavernous vasoactive drugs on cultured endothelial cells of human corpus cavernosum penis. Urology 64: 598–602

    Article  PubMed  Google Scholar 

  59. Schultheiss D, Gabouev AI, Cebotari S et al. (2005) Biological vascularized matrix for bladder tissue engineering: matrix preparation, reseeding technique and short-term implantation in a porcine model. J Urol 173: 276–280

    PubMed  Google Scholar 

  60. Seif C, Herzog J, van der Horst C et al. (2004) Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 55: 118–120

    Article  PubMed  Google Scholar 

  61. Staehler M, Rohrmann K, Haseke N et al. (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 6: 835–646

    Article  PubMed  Google Scholar 

  62. Steiner T, Knels R, Schubert J (2004) Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma. Eur Urol 46: 327–330

    Article  PubMed  Google Scholar 

  63. Sternberg K, Selent C, Hakansson N et al. (2004) Bioartificial materials in urology. Urologe A 43: 1200–1207

    Article  PubMed  Google Scholar 

  64. Steuber T, Niemela P, Haese A et al. (2005) Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 63: 13–18

    Article  PubMed  Google Scholar 

  65. Stoehr R, Brinkmann A, Filbeck T et al. (2004) No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. Oncol Rep 11: 137–141

    PubMed  Google Scholar 

  66. Stolzenburg JU, Do M, Rabenalt R et al. (2003) Endoscopic extraperitoneal radical prostatectomy: initial experience after 70 procedures. J Urol 169: 2066–2071

    Article  PubMed  Google Scholar 

  67. Stolzenburg JU, Rabenalt R, Do M et al. (2005) Endoscopic extraperitoneal radical prostatectomy: oncological and functional results after 700 procedures. J Urol 174: 1271–1275

    Article  PubMed  Google Scholar 

  68. Stope MB, Vom Dorp F, Szatkowski D et al. (2004) Rap2B-dependent stimulation of phospholipase C-epsilon by epidermal growth factor receptor mediated by c-Src phosphorylation of RasGRP3. Mol Cell Biol 24: 4664–4676

    Article  PubMed  Google Scholar 

  69. Straub B, Muller M, Krause H et al. (2003) Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer. Urology 62: 172–176

    Article  PubMed  Google Scholar 

  70. Syrovets T, Gschwend JE, Nabavi A et al. (2005) Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 280: 6170–6180

    Article  PubMed  Google Scholar 

  71. Thelen P, Wuttke W, Jarry H et al. (2004) Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol 171: 1934–1938

    Article  PubMed  Google Scholar 

  72. Thelen P, Scharf JG, Burfeind P et al. (2005) Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer. Carcinogenesis 26: 1360–1367

    Article  PubMed  Google Scholar 

  73. Thuroff S, Chaussy C, Vallancien G et al. (2003) High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 17: 673–677

    Article  PubMed  Google Scholar 

  74. Tolson J, Bogumil R, Brunst E et al. (2004) Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84: 845–856

    Article  PubMed  Google Scholar 

  75. Tomlins SA, Rhodes DR, Perner S et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648

    Article  PubMed  Google Scholar 

  76. Vanrenterghem Y, van Hooff JP, Squifflet JP et al. (2005) Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 5: 87–95

    Article  PubMed  Google Scholar 

  77. von Knobloch R, Konrad L, Barth PJ et al. (2004) Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin Cancer Res 10: 1064–1073

    Article  PubMed  Google Scholar 

  78. Weikert S, Christoph F, Schrader M et al. (2005) Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116: 100–104

    Article  PubMed  Google Scholar 

  79. Wesseling S, Stephan C, Semjonow A et al. (2003) Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy. Clin Chem 49: 887–894

    Article  PubMed  Google Scholar 

  80. Wild PJ, Herr A, Wissmann C et al. (2005) Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 11: 4415–4429

    Article  PubMed  Google Scholar 

  81. Wolff JM (2003) Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer. Onkologie 26(Suppl 7): 37–40

    Article  PubMed  Google Scholar 

  82. Zaichuk TA, Shroff EH, Emmanuel ROV et al. (2004) Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 199: 1513–1522

    Article  PubMed  Google Scholar 

  83. Zermann DH, Ishigooka M, Doggweiler-Wiygul R et al. (2005) Central autonomic innervation of the kidney. What can we learn from a transneuronal tracing study in an animal model? J Urol 173: 1033–1038

    Article  PubMed  Google Scholar 

  84. Zimmermann U, Balabanov S, Giebel J et al. (2004) Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett 209: 111–118

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin

    K. Miller & H. Krause

Authors
  1. K. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Miller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, K., Krause, H. Forschung in urologischen Universitätskliniken. Urologe 45 (Suppl 4), 15–19 (2006). https://doi.org/10.1007/s00120-006-1140-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1140-5

Search

Navigation